Cytokines Not at 'Storm' Levels in Those With Severe COVID-19
THURSDAY, Oct. 22, 2020 -- COVID-19 may not cause a cytokine storm, according to a review published online Oct. 16 in The Lancet Respiratory Medicine.
Daniel E. Leisman, M.D., from Massachusetts General Hospital in Boston, and colleagues conducted a systematic review and meta-analysis of COVID-19 studies published or posted as preprints between Nov. 1, 2019, and April 14, 2020, in which interleukin-6 concentrations in patients with severe or critical disease were recorded.
The researchers identified 25 COVID-19 studies (1,245 patients). Four trials included comparator groups, including patients with sepsis (5,320 patients), cytokine release syndrome (72 patients), and acute respiratory distress syndrome unrelated to COVID-19 (2,767 patients). The pooled mean serum interleukin-6 concentration was 36.7 pg/mL in patients with severe or critical COVID-19, but in patients with cytokine release syndrome, mean interleukin-6 concentrations were nearly 100 times higher. These concentrations were 27 times higher in patients with sepsis and 12 times higher in patients with acute respiratory distress syndrome unrelated to COVID-19.
"Our findings question the role of a cytokine storm in COVID-19-induced organ dysfunction," the authors write. "Many questions remain about the immune features of COVID-19 and the potential role of anticytokine and immune-modulating treatments in patients with the disease."
Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.
© 2021 HealthDay. All rights reserved.
Posted: October 2020
Further Support and Information on COVID-19
Read this next
Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of Jan. 19 to 22, 2021. This roundup...
FRIDAY, Jan. 22, 2021 -- Two-thirds of Americans are concerned about going to medical appointments even for an emergency when COVID-19 rates are high in their area, according to...
FRIDAY, Jan. 22, 2021 -- An antibody drug that has emergency use authorization from the U.S. Food and Drug Administration for use in early-stage COVID-19 patients with symptoms...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.